SOTIO
Manufacturing · Czech Republic · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1518/2 Jankovcova 7, Prague, Praha, Czec...Phone Number
+420 224175111Website
www.sotio.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About SOTIO
SOTIO is focused on developing next-generation immunotherapies for cancer patients, with a robust pipeline of both internally developed and in-licensed candidates for various solid tumor types. The company aims to create safer and more effective treatments through rigorous clinical development, emphasizing immunocytokines, cell therapies, and antibody-drug conjugates. SOTIO is dedicated to translating innovative science into tangible patient benefits and is actively seeking to expand its portfolio with promising oncology projects at advanced stages. Their target clients are individuals affected by solid tumors who can benefit from advanced cancer therapies.Explore more
SOTIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SOTIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if SOTIO has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when SOTIO launches new products
Click to see if SOTIO had a recent Job posting/layoffs
Check out if SOTIO is spiking on competitors!
SOTIO, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on SOTIO recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SOTIO has new funding data
Congratulate Masked Content for being promoted to Masked Content at SOTIO
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
SOTIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SOTIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SOTIO.
SOTIO financials insights
Gather financial insights about SOTIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$316.5M
SOTIO Tech Stack
A closer look at the technologies used by SOTIO
Most Recent Scoops
Person-Based
Product Development, Pharmaceuticals
Person-Based
Intellectual Property, Legal Affairs, Clinical Operations
Promotion
Executive Move
Vivi Boura has been promoted from Deputy Chief Medical Officer to the role of Chief Medical Officer.
Executive Moves, Promotion
Person-Based
Person-Based
SOTIO News & Media
SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17-Targeting ADC for Colorectal Cancer
First-in-human CADENCIA-01 study to evaluate SOT109 in patients with advanced colorectal cancers, with initial safety and efficacy signals in 12-18 months.FDA Grants Fast Track Designation to SOTIO’s SOT106 ADC for Soft Tissue Sarcoma Treatment, Accelerating Clinical Development
FDA Fast Track Designation underscores the urgency of developing new treatment options and the potential of SOT106 to address a significant medical need.European Patent Office Confirms Patent Protection for SOT201, SOTIO's Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
European Patent Office confirms patent protection for SOT201, next-gen PD-1-targeting immunocytokine currently being evaluated in a Phase 1 clinical trialEuropean Patent Office Confirms Patent Protection for SOT201, SOTIO's Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
European Patent Office confirms patent protection for SOT201, next-gen PD-1-targeting immunocytokine currently being evaluated in a Phase 1 clinical trial
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding SOTIO
Sign Up For FreeTo access detailed company insights
SOTIO is focused on developing next-generation immunotherapies for cancer patients, with a robust pipeline of both internally developed and in-licensed candidates for various solid tumor types. The company aims to create safer and more effective treatments through rigorous clinical development, emphasizing immunocytokines, cell therapies, and antib... Read More
